Announcements Trials
Browse Landscape

Phase

Phase 1 143Phase 2 95Phase NA 86Phase 1/2 63Phase 3 37Phase 2/3 5Phase 4 4Phase EARLY_PHASE1 2

Status

Completed 2Unknown 1Not yet recruiting 1

Sponsor Class

OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

Tumor-Agnostic 53Classical hematology 21Genitourinary 14Gastrointestinal 13Breast 9Other hematologic neoplasm 8Thoracic 5Other 5Plasma cell 4Lymphoid 4Gynecologic 4Dermatologic 4CNS 4Sarcoma 3NET 3Endocrine 3Myeloid 2Head & Neck 2

Conditions

Uterine Cervical Neoplasms 35Ovarian Neoplasms 31Endometrial Neoplasms 13Uterine Cervical Dysplasia 10Papillomavirus Infections 9Breast Neoplasms 9Uterine Neoplasms 7Ovarian Cysts 6Lung Neoplasms 6Stomach Neoplasms 4Neoplasms 4Esophageal Neoplasms 4Carcinoma, Ovarian Epithelial 4Polycystic Ovary Syndrome 3Ovarian Hyperstimulation Syndrome 3Liver Neoplasms 3Leiomyoma 3Head and Neck Neoplasms 3Carcinoma, Renal Cell 3Carcinoma, Non-Small-Cell Lung 3Carcinoma, Hepatocellular 3Vomiting 2Uterine Diseases 2Urinary Bladder Neoplasms 2Tobacco Use Disorder 2Squamous Intraepithelial Lesions 2Small Cell Lung Carcinoma 2Recurrence 2Peritoneal Neoplasms 2Pancreatic Neoplasms 2

Interventions

apatinib 2semaglutide 1Resistance Training 1Progestins 1Nutrition Assessment 1Megestrol Acetate 1Medroxyprogesterone Acetate 1Magnetic Resonance Spectroscopy 1Hysteroscopy 1Estrogen Replacement Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 4 × Neoplasms × Gynecologic × Clear all
NCT07462663 2026-05-13

SHAPE-ENDO

Hospital Universitari de Bellvitge

Phase 4 Not yet recruiting
82 enrolled
GynecologicOther

Endometrial Hyperplasia, Neoplasms, Obesity, Endometrial Neoplasms, Overweight

NCT03475589 2020-05-12

Study on the Adverse Drug Reactions (ADRs) of Apatinib and Their Biomarker Correlations

Sun Yat-sen University

Phase 4 Unknown
217 enrolled
Gynecologic

Neoplasms, Ovarian Neoplasms

NCT03384511 2018-02-20

The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies.

Shandong Cancer Hospital and Institute

Phase 4 Completed
38 enrolled
BreastGastrointestinalGynecologicThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Esophageal Neoplasms, Neoplasms, Ovarian Neoplasms, Stomach Neoplasms

NCT01962272 2013-10-14

The Effect of Nutritional Counseling for Cancer Patients

University of Copenhagen

Phase 4 Completed
61 enrolled
GastrointestinalGynecologic

Esophageal Neoplasms, Neoplasms, Stomach Neoplasms, Uterine Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡